Table 1 Baseline clinical characteristics of the patient
From: Correlation analysis of MR elastography and Ki-67 expression in intrahepatic cholangiocarcinoma
Variable | High Ki-67 (n = 57) | Low Ki-67 (n = 40) | p | |
|---|---|---|---|---|
Age (years)a | 62 (52, 66) | 63 (51.5, 67) | 59.5 (54, 66) | 0.615 |
Sex, male/female | 57 (58.8%)/40 (41.2%) | 41 (71.9%)/16 (28.1%) | 16 (40.0%)/24 (60.0%) | 0.002* |
AFP ≥ 20/ < 20 ng/mL | 9 (9.3%)/88 (90.7%) | 6 (10.5%)/51 (89.5%) | 3 (7.5%)/37 (92.5%) | 0.732 |
CEA ≥ 5/ < 5 ng/mL | 29 (29.9%)/68 (70.1%) | 21 (36.8%)/36 (63.2%) | 8 (20.0%)/32 (80.0%) | 0.074 |
CA19-9 ≥ 37/ < 37 ng/mL | 53 (54.6%)/44 (45.4%) | 37 (64.9%)/20 (35.1%) | 16 (40.0%)/24 (60.0%) | 0.015* |
TBil > 20.4/ ≤ 20.4 μmol/L | 5 (5.2%)/92 (94.8%) | 1 (1.8%)/56 (98.2%) | 4 (10.0%)/36 (90.0%) | 0.156 |
ALT > 35/ ≤ 35 U/L | 20 (20.6%)/77 (79.4%) | 11 (19.3%)/46 (80.7%) | 9 (22.5%)/31 (77.5%) | 0.701 |
AST > 40/ ≤ 40 U/L | 16 (16.5%)/81 (83.5%) | 8 (14.0%)/49 (86.0%) | 8 (20.0%)/32 (80.0%) | 0.436 |
ALP > 125/ ≤ 125 U/L | 33 (34.0%)/64 (66.0%) | 22 (38.6%)/35 (61.4%) | 11 (27.5%)/29 (72.5%) | 0.256 |
γGGT > 60/ ≤ 60 U/L | 53 (54.6%)/44 (45.4%) | 35 (61.4%)/22 (38.6%) | 18 (45.0%)/22 (55.0%) | 0.110 |
Chronic liver disease Y/N | 29 (29.9%)/68 (70.1%) | 17 (29.8%)/40 (70.2%) | 12 (30.0%)/28 (70.0%) | 0.777 |
Hepatitis B | 26 (89.7%) | 16 (94.1%) | 10 (83.3%) | |
Hepatitis C | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Hepatitis B + C | 1 (3.4%) | 0 (0.0%) | 1 (8.3%) | |
Other causes | 2 (6.9%) | 1 (5.9%) | 1 (8.3%) | |
Cirrhosis Y/N | 22 (22.7%)/75 (77.3%) | 12 (21.1%)/45 (78.9%) | 10 (25.0%)/30 (75.0%) | 0.648 |